Safety And Effectiveness Of Drug-Eluting Stents In Chinese Patients With Coronary Artery Disease With Off- And On-Label Indications: Results From A Single-Centre Registry

XuMin Hou,WenZheng Han,XingBiao Qiu,Hui Chen,Weiyi Fang
DOI: https://doi.org/10.1136/heartasia-2013-010316
2013-01-01
Heart Asia
Abstract:Background Off-label use of drug-eluting stents (DES) is more common than on-label use and may be associated with a persistently higher rate of adverse angiographic and clinical outcomes.Objective To evaluate the safety and effectiveness of unrestricted use of DES in everyday practice in a Chinese population.Methods Between January 2004 and May 2009 we retrospectively enrolled 1209 consecutive patients who received DES in our single centre. 84.7% of patients were treated with sirolimus-eluting stents (SES) and 15.3% of patients were treated with paclitaxel eluting stents (PES).Results 59.0% of patients (n=713) were treated for off-label indications with a significantly higher proportion of patients with previous coronary artery bypass grafting (CABG) (6.2% vs 0.6% p< 0.001). There were no differences in coronary risk factors. During 6-66 months' follow-up the rate of repeat target vessel revascularisation (TVR) was significantly higher in the off-label group (14.6% vs 9.7% p=0.011). The risk of death and myocardial infarction were not statistically different with off-label from standard use. Multivariate logistic regression showed that the independent predictors of TVR were stent type (SES vs PES HR=0.567 95% CI 0.395 to 0.813) previous CABG (HR=2.393 95% CI 1.440 to 3.977) the treatment of chronic total occlusion (HR=2.786 95% CI 1.731 to 4.484) and the treatment of left main lesion (HR=1.854 95% CI 1.022 to 3.363).Conclusions In our local unselected cohort of Chinese people off-label use of DES was safe in comparison with on-label use and associated with an excellent procedural success rate but higher TVR.
What problem does this paper attempt to address?